Ryan J. Watts - Jan 5, 2023 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
President and CEO, Director
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Jan 5, 2023
Transactions value $
-$136,512
Form type
4
Date filed
1/9/2023, 08:41 PM
Previous filing
Jan 5, 2023
Next filing
Feb 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale -$137K -4.8K -0.22% $28.44 2.22M Jan 5, 2023 See footnote F1, F2, F3, F4
holding DNLI Common Stock 217K Jan 5, 2023 Direct F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.17 to $28.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 15,000 restricted stock units held by the Reporting Person.
F4 The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F5 Includes 216,934 RSUs.